Dr. Mark L. Hartman’s training includes an A. B. from Dartmouth College, an M. D. from the University of Connecticut, an Internal Medicine residency at Dartmouth-Hitchcock Medical Center and an Endocrinology and Metabolism fellowship at the University of Virginia. He served on the University of Virginia faculty in the Department of Medicine (Endocrinology and Metabolism) from 1988 to 1997 and attained the level of Associate Professor. Since joining Eli Lilly and Company in January 1998, he has held various positions in medical affairs, global patient safety and early clinical development. His present responsibilities include phase 1 and phase 2 clinical trials in MASH and obesity.